Business News • MarketWire • Hua Medicine Announces First-Ever Successful Phase 2 Monotherapy Trial for New Class of Diabetes Drug |
Hua Medicine Announces First-Ever Successful Phase 2 Monotherapy Trial for New Class of Diabetes Drug |
|
|
Hua Medicine Announces First-Ever Successful Phase 2 Monotherapy Trial for New Class of Diabetes Drug
SHANGHAI, CHINA and SAN FRANCISCO, CA--(Marketwired - October 16, 2016) - Hua Medicine, a leading clinical stage biotech company in Shanghai, announced today positive results in the first-ever successful Phase 2 monotherapy trial of a novel drug class called glucokinase activators (GKA). The company's 4th-generation GKA, HMS5552, targets one of the key enzymes (GK) that act as a 'glucose sensor' and regulates the pathways for carbohydrate metabolism. In addition to impressive and statistically significant efficacy data, the results showed an excellent tolerability and safety profile with low risk of hypoglycemia or other side effects common in many diabetes treatments. The 12-week Proof-of-Concept clinical study was conducted in 22 leading hospital centers across China and was led by Professor Dalong Zhu, President-elect of the Chinese Diabetes Society.
View More : http://www.marketwired.com/mw/release.do?id=2166861&sourceType=3
|
|
|